Inactive Instrument

Tokai Pharmaceuticals Inc Stock price Nasdaq

Equities

US88907J1079

Biotechnology & Medical Research

Sales 2023 - Sales 2024 * - Capitalization 49.85M
Net income 2023 -40M Net income 2024 * -52M EV / Sales 2023 -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023
-1.1 x
P/E ratio 2024 *
-1.91 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 94.44%
More Fundamentals * Assessed data
Dynamic Chart
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human MT
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Eledon Pharmaceuticals, Inc. - Special Call
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation CI
Eledon Pharmaceuticals Names Eliezer Katz Chief Medical Officer MT
Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer CI
Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors CI
Noble Capital Initiates Coverage on Eledon Pharmaceuticals with Outperform Rating, $10 Price Target MT
Eledon's Investigational Antibody Used in Treatment Regimen After Pig-to-Human Heart Transplant MT
Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023 CI
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants CI
More news

Latest transcript on Tokai Pharmaceuticals Inc

Managers TitleAgeSince
Chief Executive Officer 51 20-04-30
Director of Finance/CFO 60 21-03-14
President 59 20-09-13
Members of the board TitleAgeSince
Chairman 52 17-04-30
Director/Board Member 67 20-09-13
Director/Board Member 72 17-04-30
More insiders
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing life-changing, targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). The Company's lead compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with a high affinity for CD40 Ligand (CD40L, also called CD154). Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
More about the company
  1. Stock
  2. Equities
  3. Stock Eledon Pharmaceuticals, Inc.
  4. Stock Tokai Pharmaceuticals Inc - Nasdaq